Skip to main content
×
×
Home

Choosing antipsychotic drugs in schizophrenia: A personal view

  • Paul Bebbington (a1)
Extract

Clinical psychiatrists are today in a position to prescribe an expanded range of antipsychotic drugs for the treatment of schizophrenia and related psychoses. The introduction of chlorpromazine in 1952 was followed by many others. They varied in potency and in side-effect profile, but they shared the capacity to cause extrapyramidal side-effects (EPS). These side-effects were produced by a mechanism intrinsically similar to that responsible for the antipsychotic effectiveness of the drug. They seemed to be the price that had to be paid for the resolution of psychotic symptoms.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Choosing antipsychotic drugs in schizophrenia
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Choosing antipsychotic drugs in schizophrenia
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Choosing antipsychotic drugs in schizophrenia
      Available formats
      ×
Copyright
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
Hide All
Bebbington, P. E. (1995) The content and context of compliance. International Clinical Psychopharmacology, 9 (Suppl.), 4150.
Bollini, P., Pampallona, S., Orza, M. J., Adams, M. E. et al (1994) Antipsychotic drugs: Is more worse? A meta-analysis of the published randomized control trials. Psychological Medicine, 24, 307316.
British Medical Association & Royal Pharmaceutical Society (1999) British National Formulary. London & Wallingford: BMJ Books & Pharmaceutical Press.
Buchanan, A. (1992) A two-year prospective study of treatment compliance in patients with schizophrenia. Psychological Medicine, 22, 787797.
Farde, L, Nordstrom, A. L., Wiesel, F. A., et al (1992) Positron emission topographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Archives of General Psychiatry, 49, 538544.
Geddes, J., Freemantle, N., Harrison, P., et al for the National Schizophrenia Guideline Development Group (2000) Atypical antipsychotics in the treatment of schizophrenia – systematic overview and meta-regression analysis. BMJ, 321, 13711376.
Hanson, R. W. (1986) Physician-patient communication and compliance. In: Compliance: The Dilemma of Chronically III (eds Gerner, K. E. & Nehemkis, A. M.), pp. 182212. NewYork: Springer.
Kissling, W. (1994) Compliance, quality assurance and standards for relapse prevention in schizophrenia. Acta Psychiatrica Scandinavica, 328 (Suppl), 1624.
Ley, P. (1982) Satisfaction, compliance and communication. British Journal of Clinical Psychology, 21, 241254.
Meltzer, H. Y. (1990) Defining treatment refractoriness in schizophrenia. Schizophrenia Bulletin, 16, 563565.
Peuskens, J., on behalf of the Risperidone Study Group (1995) Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. British Journal of Psychiatry, 166, 712726.
Pfeiffer, W., Kockott, G., Fischl, B., et al (1991) Unerwunschte wirkungen psychopharmakologischer langzeittherapie auf die sexuellen funktionen. Psychiatrische Praxis, 18, 9298.
Silverstone, T., Smith, G. & Goodall, E. (1988) Prevalence of obesity in patients receiving depot antipsychotics. British Journal of Psychiatry, 153, 214217.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

BJPsych Bulletin
  • ISSN: 0955-6036
  • EISSN: 1472-1473
  • URL: /core/journals/bjpsych-bulletin
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 2
Total number of PDF views: 20 *
Loading metrics...

Abstract views

Total abstract views: 111 *
Loading metrics...

* Views captured on Cambridge Core between 2nd January 2018 - 19th July 2018. This data will be updated every 24 hours.

Choosing antipsychotic drugs in schizophrenia: A personal view

  • Paul Bebbington (a1)
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *